New Flexible Auditory Brainstem Implant Offers Hope for Patients with Severe Hearing Loss
Release time:
2025-04-25
A research team from the Swiss Federal Institute of Technology Lausanne (EPFL) recently published a groundbreaking achievement in Nature Biomedical Engineering: the world’s first flexible auditory brainstem implant (ABI). This innovative technology aims to address the side effects caused by the rigid structure of traditional ABIs, offering a more precise and safe hearing restoration solution for patients with severe cochlear nerve damage who cannot benefit from cochlear implants.
Challenges of Traditional ABI Technology: Side Effects and Limited Efficacy
Since their inception, ABIs have been considered a "last resort" for patients ineligible for cochlear implants. However, conventional rigid electrode arrays struggle to conform to the brainstem’s complex curvature, leading to current spread and unintended nerve activation. Clinically, doctors often deactivate most electrodes to avoid side effects such as dizziness and facial twitching, leaving patients with only vague sound perception and an inability to discern speech.
"These limitations severely hinder the practical utility of ABIs, offering minimal improvement to patients’ quality of life," noted Professor Stéphanie P. Lacour, head of EPFL’s Soft Bioelectronic Interfaces Laboratory. "We need a solution that naturally conforms to brain tissue and delivers precise stimulation."
Flexible Breakthrough: Millimeter-Thick Film Adapts to Brainstem Curvature
The team leveraged advancements in materials science and microfabrication to develop a flexible ABI just millimeters thick. The device embeds micron-sized platinum electrodes into a silicone film, creating a bendable array that conforms seamlessly to the cochlear nucleus surface (with a radius as small as 3 mm). Compared to rigid implants, this flexible design reduces current leakage risks and enables more electrodes to operate simultaneously, enhancing sound resolution.
"Seamless contact between flexible electrodes and tissue is key," explained co-first author Alix Trouillet. "This not only lowers stimulation thresholds but also allows more electrodes to activate, laying the groundwork for high-resolution hearing restoration." The team also utilized microlithography to customize electrode layouts, with future plans to adjust electrode numbers (currently 11) and configurations for patient-specific frequency tuning.
Successful Animal Trials: Macaques "Understand" Electrical Pulse Signals
To validate the flexible ABI’s efficacy, the team conducted months of behavioral experiments on hearing-capable macaques. The monkeys were trained to distinguish between continuous tones using a joystick. Gradually, natural sounds were replaced with ABI-generated electrical stimuli, and eventually, fully artificial signals. Results showed the macaques could accurately differentiate subtle variations between electrode pairs, processing electrical pulses similarly to real sounds.
"The animals’ voluntary triggering of stimuli indicates no discomfort from artificial hearing," emphasized co-first author Emilie Revol. Notably, no facial twitching or side effects occurred, and the implant demonstrated long-term stability without displacement—a common issue causing performance degradation in traditional ABIs.
Clinical Prospects: Potential for Intraoperative Testing
Despite promising results, the team acknowledges challenges such as medical material certification and long-term reliability testing before clinical use. Prof. Lacour revealed plans to collaborate with clinical partners in Boston for short-term intraoperative testing of flexible electrodes during human ABI surgeries, comparing their ability to reduce unintended nerve activation versus traditional devices.
"If intraoperative trials succeed, flexible ABIs could usher in a new era of hearing rehabilitation," Lacour stated. Future efforts will focus on increasing electrode density for improved sound resolution and exploring broader applications in neuroregulation.
Broader Implications
EPFL’s research not only brings hope to patients with severe hearing loss but also sets a benchmark for flexible bioelectronic devices. As the technology evolves and advances toward clinical adoption, flexible ABIs may become the next milestone in neural repair, redefining the boundaries of human-machine interaction.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
